Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 12, pp. 1330-1338
Closed Access | Times Cited: 290

Showing 1-25 of 290 citing articles:

mRNA vaccines — a new era in vaccinology
Norbert Pardi, Michael J. Hogan, Frederick Porter, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 4, pp. 261-279
Open Access | Times Cited: 3594
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo González, Catharina Hagerling, Zena Werb
Genes & Development (2018) Vol. 32, Iss. 19-20, pp. 1267-1284
Open Access | Times Cited: 1767
Therapeutic cancer vaccines
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J.M. Melief, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 360-378
Closed Access | Times Cited: 1110
Therapeutic cancer vaccines
Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, et al.
Journal of Clinical Investigation (2015) Vol. 125, Iss. 9, pp. 3401-3412
Open Access | Times Cited: 1046
Dendritic cell-based immunotherapy
Rachel Lubong Sabado, Sreekumar Balan, Nina Bhardwaj
Cell Research (2016) Vol. 27, Iss. 1, pp. 74-95
Open Access | Times Cited: 772
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 426
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 414
Engineering dendritic cell vaccines to improve cancer immunotherapy
Caleb R. Perez, Michele De Palma
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 405
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang, Xing Huang, Gang Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 365
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
Kalijn F. Bol, Gerty Schreibelt, Winald R. Gerritsen, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 8, pp. 1897-1906
Open Access | Times Cited: 340
Dendritic cell biology and its role in tumor immunotherapy
Ying-Ying Wang, Ying Xiang, Victoria W. Xin, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 321
Dendritic Cell–Based Cancer Vaccines
P.M.L. Santos, Lisa H. Butterfield
The Journal of Immunology (2018) Vol. 200, Iss. 2, pp. 443-449
Open Access | Times Cited: 308
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
Abhishek D. Garg, Pierre G. Coulie, Benoı̂t J. Van den Eynde, et al.
Trends in Immunology (2017) Vol. 38, Iss. 8, pp. 577-593
Open Access | Times Cited: 307
mRNA therapeutics in cancer immunotherapy
Jan D. Beck, Daniel Reidenbach, Nadja Salomon, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 285
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Shuqin Xu, Kunpeng Yang, Rose Li, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6582-6582
Open Access | Times Cited: 280
Emerging Concepts and Technologies in Vaccine Development
Morgan Brisse, Sophia M. Vrba, Natalie M. Kirk, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 261
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Alfonso R. Sánchez-Paulete, Álvaro Teijeira, Francisco J. Cueto, et al.
Annals of Oncology (2017) Vol. 28, pp. xii44-xii55
Open Access | Times Cited: 233
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sébastien Anguille, Ann L. Van de Velde, Evelien Smits, et al.
Blood (2017) Vol. 130, Iss. 15, pp. 1713-1721
Open Access | Times Cited: 198
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Karim Vermaelen
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 195
Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
Zhenyu Ding, Qing Li, Rui Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 195
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Itziar Gómez-Aguado, Julen Rodríguez-Castejón, Mónica Vicente-Pascual, et al.
Nanomaterials (2020) Vol. 10, Iss. 2, pp. 364-364
Open Access | Times Cited: 188
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Kalijn F. Bol, Gerty Schreibelt, Katrin Rabold, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 150
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
Alice Mougel, Magali Terme, Corinne Tanchot
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 147
Current Advances in the Treatment of BRAF-Mutant Melanoma
Hima Patel, Nour Yacoub, Rosalin Mishra, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 482-482
Open Access | Times Cited: 143
Clinical and immunological effects of mRNA vaccines in malignant diseases
Annkristin Heine, Stefan Juranek, Peter Brossart
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 125
Page 1 - Next Page

Scroll to top